Meisam Naeimi Kararoudi

This researcher develops engineered immune cell therapies for cancer, including CAR-modified natural killer (NK) cells and gamma-delta T cells, which are immune cells re-programmed in the lab to recognize and kill tumor cells without needing to be matched to an individual patient ('off-the-shelf' therapy). Earlier work in the publication record also covers vascular biology, metabolic disease, and gene-editing approaches for genetic disorders, suggesting a research path that has evolved toward cell and gene therapy for cancer immunotherapy. This work would suit students interested in immunology, gene editing (such as CRISPR-based tools), and translational cancer therapeutics.

Publication output has grown over the last decade, rising from about 1 paper in 2017 to a peak of 8 in 2025, with an average of about 5 papers per year over the last five years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026